Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma


Andreas Seeber, Kai Zimmer, Florian Kocher, Alberto Puccini, Joanne Xiu, Chadi Nabhan, Andrew Elliott, Richard M Goldberg, Axel Grothey, Anthony F Shields, Francesca Battaglin, Wafik S El-Deiry, Philip A Philip, John L Marshall, Michael Hall, W Michael Korn, Heinz-Josef Lenz, Dominik Wolf, Clemens Feistritzer, Gilbert Spizzo


BRCA and PALB2 mutations were found in a significant subgroup of PDACs. These mutations were associated with a distinct molecular profile potentially predictive for response to immune-checkpoint inhibitor therapy. Therefore, these data provide a rationale to evaluate PARP inhibitors in combination with immune-checkpoint inhibitors in patients with BRCA/PALB2-mutated PDAC.

External Link